Next Article in Journal
Hitting the Bull’s-Eye in Metastatic Cancers—NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death
Next Article in Special Issue
Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease
Previous Article in Journal
Etomidate and Ketamine: Residual Motor and Adrenal Dysfunction that Persist beyond Recovery from Loss of Righting Reflex in Rats
Previous Article in Special Issue
Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
Open AccessReview

γδ T Cell Immunotherapy—A Review

Transfusion Medicine and Cell Processing, Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
Center for Therapeutic Innovation, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan
Authors to whom correspondence should be addressed.
Academic Editor: Shin Mineishi
Pharmaceuticals 2015, 8(1), 40-61;
Received: 6 January 2015 / Accepted: 2 February 2015 / Published: 12 February 2015
(This article belongs to the Special Issue Cell Therapy)
Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy. View Full-Text
Keywords: cancer immunotherapy; nitrogen-containing bisphosphonate; phosphoantigen; tumor; Vγ9Vδ2 T cell cancer immunotherapy; nitrogen-containing bisphosphonate; phosphoantigen; tumor; Vγ9Vδ2 T cell
Show Figures

Figure 1

MDPI and ACS Style

Kobayashi, H.; Tanaka, Y. γδ T Cell Immunotherapy—A Review. Pharmaceuticals 2015, 8, 40-61.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop